Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Potential Biomarkers of Immune Protection in Human Leishmaniasis Publisher Pubmed



Rostami MN1 ; Khamesipour A2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran
  2. 2. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, 14155-6383, Iran

Source: Medical Microbiology and Immunology Published:2021


Abstract

Leishmaniasis is a vector-borne neglected tropical disease endemic in over 100 countries around the world. Available control measures are not always successful, therapeutic options are limited, and there is no vaccine available against human leishmaniasis, although several candidate antigens have been evaluated over the last decades. Plenty of studies have aimed to evaluate the immune response development and a diverse range of host immune factors have been described to be associated with protection or disease progression in leishmaniasis; however, to date, no comprehensive biomarker(s) have been identified as surrogate marker of protection or exacerbation, and lack of enough information remains a barrier for vaccine development. Most of the current understanding of the role of different markers of immune response in leishmaniasis has been collected from experimental animal models. Although the data generated from the animal models are crucial, it might not always be extrapolated to humans. Here, we briefly review the events during Leishmania invasion of host cells and the immune responses induced against Leishmania in animal models and humans and their potential role as a biomarker of protection against human leishmaniasis. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Related Docs
View other Related Docs
1. Tumour Necrosis Factor-Alpha (Tnf-Α) and Its Soluble Receptor Type 1 (Stnfr I) in Human Active and Healed Leishmaniases, Parasite Immunology (2016)
2. Plasma Levels of Tumor Necrosis Factor-Alpha (Tnf-Α), Tnf-Α Soluble Receptor Type 1 (Stnfr I) and Il-22 in Human Leishmaniasis, Tropical Biomedicine (2015)
3. Unraveling the Role of Natural Killer Cells in Leishmaniasis, International Immunopharmacology (2023)
4. Immune Response in Cutaneous Leishmaniasis Patients With Healing Vs. Non-Healing Lesions, Iranian Journal of Microbiology (2020)
5. Comparison of Cytokine Profile of Ifn-Γ, Il-5 and Il-10 in Cutaneous Leishmaniasis Using Pbmc Vs. Whole Blood, Iranian Journal of Microbiology (2019)
6. Melittin As a Promising Anti-Protozoan Peptide: Current Knowledge and Future Prospects, AMB Express (2021)
7. Evolution of Antigen-Specific Immune Responses in Cutaneous Leishmaniasis Patients, Parasite Immunology (2021)
8. Comparison of Pro-Inflammatory Cytokines of Non-Healing and Healing Cutaneous Leishmaniasis, Scandinavian Journal of Immunology (2017)
Experts (# of related papers)
View all Related Experts
Mahdi Mohebali (13)
Homa Hajjaran (3)
Other Related Docs
9. Coadminstration of L. Major Amastigote Class I Nuclease (Rlmacin) With Lpd Nanoparticles Delays the Progression of Skin Lesion and the L. Major Dissemination to the Spleen in Balb/C Mice-Based Experimental Setting, Acta Tropica (2016)
10. A Comparative Evaluation of Regulatory T Cells Profile Among Acute and Chronic Cutaneous Leishmaniasis Using Flow Cytometry, Iranian Journal of Parasitology (2019)
11. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
12. Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis, Microorganisms (2020)
13. Vaccines for Preventing Cutaneous Leishmaniasis, Cochrane Database of Systematic Reviews (2018)
14. Evaluation of Th17 Associated Antigen in Old World Cutaneous Leishmaniasis: A Comparative Study in Acute Versus Chronic Human Cutaneous Leishmaniasis Using Immunohistochemistry, Tropical Biomedicine (2019)
15. The Outcome of Arginase Activity Inhibition in Balb/C Mice Hosting Leishmania Tropica, Parasite Immunology (2020)
16. Antileishmanial Activity of Urtica Dioica Extract Against Zoonotic Cutaneous Leishmaniasis, PLoS Neglected Tropical Diseases (2020)
17. Evaluation of Cellular Immune Responses in Dogs Immunized With Alum-Precipitated Autoclaved Leishmania Major Along With Bcg and Imiquimod, Iranian Journal of Parasitology (2021)
18. Immune Responses in Cutaneous Leishmaniasis: In Vitro Thelper1/Thelper2 Cytokine Profiles Using Live Versus Killed Leishmania Major, Journal of Arthropod-Borne Diseases (2021)
19. T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania Major Lipophosphoglycan 3, Immunological Investigations (2016)
20. The Role of Lpd-Nanoparticles Containing Recombinant Major Surface Glycoprotein of Leishmania (Rgp63) in Protection Against Leishmaniasis in Murine Model, Immunopharmacology and Immunotoxicology (2018)
21. Leishmania Tarentolae Secreting the Sand Fly Salivary Antigen Ppsp15 Confers Protection Against Leishmania Major Infection in a Susceptible Balb/C Mice Model, Molecular Immunology (2015)
22. Engineering and Design of Promising T-Cell-Based Multi-Epitope Vaccine Candidates Against Leishmaniasis, Scientific Reports (2023)
23. An Overview of Leishmanization Experience: A Successful Control Measure and a Tool to Evaluate Candidate Vaccines, Acta Tropica (2019)
24. Multilocus Sequence Typing Analysis of Leishmania Clinical Isolates From Cutaneous Leishmaniasis Patients of Iran, Infection# Genetics and Evolution (2020)
25. In Vitro and in Vivo Therapeutic Potentials of 6-Gingerol in Combination With Amphotericin B for Treatment of Leishmania Major Infection: Powerful Synergistic and Multifunctional Effects, International Immunopharmacology (2021)
26. Pegylation of Cationic Liposomes Encapsulating Soluble Leishmania Antigens Reduces the Adjuvant Efficacy of Liposomes in Murine Model, Parasite Immunology (2017)
27. Cationic Liposomes Formulated With a Novel Whole Leishmania Lysate (Wll) As a Vaccine for Leishmaniasis in Murine Model, Immunobiology (2018)
28. The Role of Iscomatrix Bilayer Composition to Induce a Cell Mediated Immunity and Protection Against Leishmaniasis in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2016)
29. Analysis of Human B Cell Response to Recombinant Leishmania Lpg3, Asian Pacific Journal of Tropical Medicine (2015)
30. Immunization Against Leishmania Major Infection in Balb/C Mice Using a Subunit-Based Dna Vaccine Derived From Tsa, Lmsti1, Kmp11, and Lack Predominant Antigens, Iranian Journal of Basic Medical Sciences (2019)
31. The Role of Mpl and Imiquimod Adjuvants in Enhancement of Immune Response and Protection in Balb/C Mice Immunized With Soluble Leishmania Antigen (Sla) Encapsulated in Nanoliposome, Artificial Cells# Nanomedicine and Biotechnology (2018)
32. Sambucus Ebulus Extract Stimulates Cellular Responses in Cutaneous Leishmaniasis, Parasite Immunology (2019)
33. Leishmania Tropica Infected Human Lesions: Whole Genome Transcription Profiling, Acta Tropica (2017)
34. Human Immune Response to Phlebotomus Sergenti Salivary Gland Antigens in a Leishmaniasis-Endemic Focus in Iran, Pathogens and Global Health (2020)
35. Comparing Acute and Chronic Human Cutaneous Leishmaniasis Caused by Leishmania Major and Leishmania Tropica Focusing on Arginase Activity, Journal of the European Academy of Dermatology and Venereology (2016)
36. Human Neutrophil Peptide 1 As Immunotherapeutic Agent Against Leishmania Infected Balb/C Mice, PLoS Neglected Tropical Diseases (2017)
37. Leishmanicidal Potentials of Gossypium Hirsutum Extract and Its Fractions on Leishmania Major in a Murine Model: Parasite Burden, Gene Expression, and Histopathological Profile, Journal of Medical Microbiology (2021)
38. Evaluation of a Novel Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Against Leishmania Infantum in Balb/C Mice, Parasite Immunology (2016)
39. Old World Cutaneous Leishmaniasis in Iran: Clinical Variants and Treatments, Journal of Dermatological Treatment (2021)
40. Evaluation of Expression Variations in Virulence-Related Genes of Leishmania Major After Several Culture Passages Compared With Phlebotomus Papatasi Isolated Promastigotes, PLoS ONE (2023)
41. Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania Major (Alum-Alm) Vaccine Mixed With Bcg Plus Imiquimod Vs. Placebo Control Group, Iranian Journal of Parasitology (2015)
42. F Protein Increases Cd4+Cd25+ T Cell Population in Patients With Chronic Hepatitis C, Pathogens and Disease (2015)
43. Design of a Polytopic Construct of Lack, Tsa and Gp63 Proteins for the Diagnosis of Cutaneous Leishmaniasis: An in Silico Strategy, Journal of Asia-Pacific Entomology (2022)
44. Evaluation of Immune Response Against Leishmaniasis in Balb/C Mice Immunized With Cationic Dotap/Dope/Chol Liposomes Containing Soluble Leishmania Major Antigens, Iranian Journal of Parasitology (2019)
45. An Alphavirus-Derived Self-Amplifying Mrna Encoding Ppsp15-Lmsti1 Fusion Protein for the Design of a Vaccine Against Leishmaniasis, Parasitology International (2022)
46. Detection of Potentially Diagnostic Leishmania Antigens With Western Blot Analysis of Sera From Patients With Cutaneous and Visceral Leishmaniases, Iranian Journal of Parasitology (2017)
47. Comparative Expression Profile Analysis of Apoptosis-Related Mirna and Its Target Gene in Leishmania Major Infected Macrophages, Iranian Journal of Parasitology (2020)
48. Naloxone Effects Against Cutaneous Leishmaniasis Caused by Leishmania Major Strain Mrho/Ir/75/Er in the Balb/C Mice, Infectious Disorders - Drug Targets (2023)
49. Effect of Leishmania Rna Virus 2 on Virulence Factors and Cytokines Gene Expression in a Human Macrophage Infected With Leishmania Major: A Preliminary Study, Experimental Parasitology (2023)
50. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)